Literature DB >> 18383374

Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.

David Langleben1, Stylianos E Orfanos, Michele Giovinazzo, Andrew Hirsch, Murray Baron, Jean-Luc Senécal, Apostolos Armaganidis, John D Catravas.   

Abstract

OBJECTIVE: Pulmonary endothelial dysfunction is intertwined with the development and progression of pulmonary arterial hypertension (PAH). Pulmonary endothelium is an active metabolic tissue in healthy human subjects. This study was undertaken to determine the effects of PAH on pulmonary endothelial angiotensin-converting enzyme (ACE) activity and to identify differences between common PAH types, i.e., PAH related to connective tissue disease (PAH-CTD) versus idiopathic PAH (IPAH).
METHODS: Nineteen patients with PAH-CTD, 25 patients with IPAH, and 23 control subjects were evaluated. The single-pass transpulmonary percent metabolism (%M) and hydrolysis (both reflecting enzyme activity per capillary) of an ACE synthetic substrate were determined. In addition, the calculated functional capillary surface area (FCSA), normalized to body surface area (BSA), was determined.
RESULTS: The %M values in patients with PAH-CTD (mean+/-SEM 53.6+/-3.6%) were significantly reduced compared with those in control subjects (P<0.01) and those in patients with IPAH (P<0.03), but were similar between the IPAH and control groups (mean+/-SEM 66.2+/-3.6% and 74.7+/-2.7%, respectively). Substrate hydrolysis was also significantly reduced in patients with PAH-CTD. The FCSA/BSA was significantly reduced in patients with PAH-CTD (mean+/-SEM 1,068+/-118 ml/minute/m2) and in patients with IPAH (1,443+/-186 ml/minute/m2) compared with that in controls (2,948+/-245 ml/minute/m2; P<0.01 for both). At a given cardiac index, the FCSA/BSA tended to be lower in the PAH-CTD group than in the IPAH group. Moreover, unlike in IPAH, a linear relationship between the FCSA/BSA and the diffusing capacity for carbon monoxide (DLCO) was observed in PAH-CTD (r=0.54, P<0.03).
CONCLUSION: The metabolically functional pulmonary capillary bed appears to be reduced to an equal extent in PAH-CTD and IPAH. However, %M and hydrolysis appear to be reduced in PAH-CTD but not in IPAH, reflecting relatively diminished ACE activity on the pulmonary capillary endothelial cells of patients with PAH-CTD, and showing that pulmonary endothelial metabolic function differs between PAH types. This study also provides the first functional evidence that a reduced DLCO value in patients with PAH-CTD is related to the degree of FCSA loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383374     DOI: 10.1002/art.23405

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

2.  The frequency of pulmonary hypertension in patients with juvenile scleroderma.

Authors:  Amra Adrovic; Funda Oztunc; Kenan Barut; Aida Koka; Refet Gojak; Sezgin Sahin; Tuncalp Demir; Ozgur Kasapcopur
Journal:  Bosn J Basic Med Sci       Date:  2015-08-22       Impact factor: 3.363

Review 3.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases.

Authors:  Yuko Takahashi; Shiori Haga; Yukihito Ishizaka; Akio Mimori
Journal:  Arthritis Res Ther       Date:  2010-05-14       Impact factor: 5.156

5.  Preclinical pulmonary capillary endothelial dysfunction is present in brain dead subjects.

Authors:  Constantinos Glynos; Chariclea Athanasiou; Anastasia Kotanidou; Ioanna Korovesi; Katerina Kaziani; Olga Livaditi; Ioanna Dimopoulou; Nikolaos A Maniatis; Iraklis Tsangaris; Charis Roussos; Apostolos Armaganidis; Stylianos E Orfanos
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 6.  Molecular imaging of the pulmonary circulation in health and disease.

Authors:  Jocelyn Dupuis; François Harel; Quang T Nguyen
Journal:  Clin Transl Imaging       Date:  2014-09-09

Review 7.  Novel biomarkers for pulmonary arterial hypertension.

Authors:  Anjum Anwar; Gregoire Ruffenach; Aman Mahajan; Mansoureh Eghbali; Soban Umar
Journal:  Respir Res       Date:  2016-07-20

8.  Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Authors:  David Langleben; Stylianos Orfanos
Journal:  Pulm Circ       Date:  2017-06-20       Impact factor: 3.017

9.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10

10.  Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality.

Authors:  Katerina Kaziani; Alice G Vassiliou; Anastasia Kotanidou; Chariclea Athanasiou; Ioanna Korovesi; Konstantinos Glynos; Stylianos E Orfanos
Journal:  Infect Dis Ther       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.